Product Description
Idorsia is developing Lucerastat as a treatment for Fabry disease. (Sourced from: https://www.idorsia.com/media/news-details?newsId=2608540)
Mechanisms of Action: GCS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Idorsia
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Canada, France, Germany, Norway, Poland, Spain, United Kingdom, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Fabry Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ID-069A302 | P3 |
Active, not recruiting |
Fabry Disease |
2025-10-29 |
|
2018-002210-12 | P3 |
Unknown status |
Fabry Disease |
2025-09-18 |